Mucin Glycans: A Target for Cancer Therapy.

Area of Science:

• Biochemistry
• Glycobiology
• Cancer Biology

Background:

• Mucin glycans form the mucus barrier, protecting against damage and pathogens.
• Aberrant mucin glycan expression is linked to cancer development through various mechanisms.
• Mucins are classified as secreted or transmembrane, with organ- and cell-specific expression.

Purpose of the Study:

• To summarize mucin glycosylation types and mechanisms of aberrant expression.
• To describe the role of abnormal mucin glycans in cancer development.
• To review MUC1-targeted cancer therapies, including novel CAR-M approaches.

Main Methods:

• Literature review of mucin glycosylation.
• Analysis of mechanisms linking aberrant mucin glycans to cancer.
• Summary of MUC1-based therapeutic strategies (antibodies, vaccines, radiopharmaceuticals, CAR-T, CAR-M).

Main Results:

• Identified O-GalNAc and N-glycosylation as key mucin glycosylation types.
• Detailed mechanisms by which abnormal mucin glycans promote cancer progression.
• Highlighted MUC1 as a key target for cancer diagnosis and therapy.

Conclusions:

• Targeting mucin glycans, especially MUC1, is a promising strategy for cancer treatment.
• Emerging therapies like CAR-M show potential for improving cancer patient outcomes.
• Further research into mucin glycan biology is crucial for advancing cancer therapies.